PATENT CLAIM ANALYSIS

Application Number: 16040450
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["514", "354000"]

Abstract:
Provided herein are lyophilized formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereisomer or mixture of stereisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Methods of using the formulations and dosage forms for treating, managing, and/or preventing cancer are also provided herein.

Claim (Index 39):
The method of  claim 38 , wherein the method comprises administering the formulation intravenously.

Metadata:
- Claim Count in Document: 107.0
- Percentile: 95.0
- Lexical Diversity: 1.51064
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15400791', '15614434', '15400630', '15400766', '14405317']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7079093955740515
- 35 USC 102 Novelty (BERT): 0.5775240740461905
- Combined Prediction Score: 0.6948708634212655
- Mean Citation Score: 358.38842
- Max Citation Score: 502.81305
- Similarity Product: 343.3596490497618

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test